Quantcast
Home > Quotes > REGN
REGN

Regeneron Pharmaceuticals, Inc. Common Stock (REGN) Quote & Summary Data

$294.68
*  
1.92
0.65%
Get REGN Alerts
*Delayed - data as of May 22, 2018  -  Find a broker to begin trading REGN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
395
Today's High / Low
$ 299.71 / $ 293.53
Share Volume
441,936
50 Day Avg. Daily Volume
931,118
Previous Close
$ 296.60
52 Week High / Low
$ 543.5518 / $ 281.89
Market Cap
31,784,531,933
P/E Ratio
23.92
Forward P/E (1y)
17.55
Earnings Per Share (EPS)
$ 12.32
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.94

Intraday Chart

Shares Traded

Share Volume:
441,936
50 Day Avg. Daily Volume:
931,118

P/E Ratio

P/E Ratio:
23.92
Forward P/E (1y):
17.55
Earnings Per Share (EPS):
$ 12.32

Trading Range

The current last sale of $294.68 is 4.54% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 299.71 $ 543.5518
 Low: $ 293.53 $ 281.89

ETFs with REGN as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
3.87% iShares Nasdaq Biotechnology Index Fund (IBB) -1.06 (-0.99%)
0% Proshares UltraPro Nasdaq Biotechnology (UBIO) -3.81 (-11.12%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  ... More ...  

Risk Grade

Where does REGN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 297.88
Open Date:
May 22, 2018
Close Price:
$ 294.68
Close Date:
May 22, 2018

Consensus Recommendation

Analyst Info